查找地点
有关时间、上门服务和预约查找地点
有关时间、上门服务和预约THRB
This assay currently is not available in New York state.
14 - 28 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
14 - 28 days 14 - 28 days |
14 - 28 days 14 - 28 days |
Whole blood; oral swab or extracted DNA (from blood or oral swab only)
Whole blood |
Whole blood; oral swab or extracted DNA (from blood or oral swab only) |
Whole blood: 4 mL; oral swab: 3 swabs; or extracted DNA: contact MNG Genetic Services 844-664-8378 (844-MNGTEST)
|
Whole blood: 4 mL; oral swab: 3 swabs; or extracted DNA: contact MNG Genetic Services 844-664-8378 (844-MNGTEST) |
Whole blood: 2 mL; oral swab: 1 swab; or extracted DNA: contact MNG Genetic Services 844-664-8378 (844-MNGTEST)
Whole blood: lavender-top (EDTA) tube; oral swab: OCD-100 DNA Genotek; or extracted DNA: contact MNG Genetic Services 844-664-8378 (844-MNGTEST)
|
Whole blood: lavender-top (EDTA) tube; oral swab: OCD-100 DNA Genotek; or extracted DNA: contact MNG Genetic Services 844-664-8378 (844-MNGTEST) |
Whole blood: standard phlebotomy; oral swab: follow kit instructions; or extracted DNA: contact MNG Genetic Services 844-664-8378 (844-MNGTEST)
|
Whole blood: standard phlebotomy; oral swab: follow kit instructions; or extracted DNA: contact MNG Genetic Services 844-664-8378 (844-MNGTEST) |
Maintain specimen at room temperature or refrigerate at 4°C. Do not freeze.
|
Maintain specimen at room temperature or refrigerate at 4°C. Do not freeze. |
• Room temperature: whole blood: 14 days; swab: 60 days
• Refrigerated: whole blood: 30 days; swab: 60 days
• Frozen: do not freeze
• Room temperature: • Refrigerated: Blood: 5 days; Swab: 60 days; DNA: 30 days • Frozen: Blood: Do not freeze; Swab: 60 days; DNA: Indefinitely |
• Room temperature: whole blood: 14 days; swab: 60 days • Refrigerated: whole blood: 30 days; swab: 60 days • Frozen: do not freeze |
Frozen or hemolyzed specimen; quantity not sufficient for analysis; improper container
Frozen |
Frozen or hemolyzed specimen; quantity not sufficient for analysis; improper container |
Diagnostic testing
This assay will not consistently detect mosaicism or rule out the presence of large chromosomal aberrations, including rearrangements and inversions that do not change copy number of genomic regions. This NGS assay does not detect repeat expansions. False positive or false negative results may occur for reasons that include insufficient information available about rare genetic variants, sex chromosome abnormalities, pseudogene interference, homologous regions, blood transfusions, bone marrow transplantation, somatic or tissue-specific mosaicism/heteroplasmy, mislabeled samples or erroneous representation of family relationships. For panels with mitochondrial DNA assessment, low levels of heteroplasmy may not be reliably detected. Interpretation of the clinical significance of gene variations is limited by information about the variant that is available at the time of reporting and by the quality and quantity of clinical information provided with the sample. The interpretation of the clinical significance of variants may change.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
This assay will not consistently detect This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. |
This assay will not consistently detect mosaicism or rule out the presence of large chromosomal aberrations, including rearrangements and inversions that do not change copy number of genomic regions. This NGS assay does not detect repeat expansions. False positive or false negative results may occur for reasons that include insufficient information available about rare genetic variants, sex chromosome abnormalities, pseudogene interference, homologous regions, blood transfusions, bone marrow transplantation, somatic or tissue-specific mosaicism/heteroplasmy, mislabeled samples or erroneous representation of family relationships. For panels with mitochondrial DNA assessment, low levels of heteroplasmy may not be reliably detected. Interpretation of the clinical significance of gene variations is limited by information about the variant that is available at the time of reporting and by the quality and quantity of clinical information provided with the sample. The interpretation of the clinical significance of variants may change. This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. |
Next-generation sequencing to identify genetic variants, including single nucleotide variants (SNVs), insertions, deletions and copy number variants (CNVs)
Nuclear Gene Copy Number Variant Assessment: Next Generation Sequencing data used to call SNPs and small indels are assessed with Illumina’s DRAGEN (Dynamic Read Analysis for GENomics) Bio-IT Platform. Genes listed in ClinVar with intragenic pathogenic deletions are padded with additional intronic probes to allow single exon resolution CNV detection (list based on ClinVar Deletion Database: January 2019 release). For other genes, large deletions (>10 exons) can be detected. The resolution of this analysis can vary depending on region-specific features. Analytical sensitivity is estimated to be >95%. Results Interpretation: Results should be used in the context of available clinical information and should not be used as the sole basis for patient management or treatment. Genetic counseling is recommended. Variants are assessed according to ACMG criteria.2 This report contains interpretation of pathogenic and likely pathogenic variants (by ACMG Criteria) as well as variants of uncertain significance (VUS) with pathogenic predictions related to the clinical information provided. Variants not reported: (1) Variants classified as benign or likely benign by ACMG Criteria; (2) VUS with benign or likely benign predictions; (3) variants related to carrier status; (4) polymorphisms with implications in drug response (pharmacogenomics variants). We will reanalyze the data periodically at the clinician’s request to allow potential reinterpretation based on new research or evidence. GnomAD abbreviations for population frequency data: African/African American (AFR), Latino (AMR), Ashkenazi Jewish (ASJ), East Asian (EAS), Finnish (FIN), Non-Finnish European (NFE), South Asian (SAS), Other (OTH). |
Next-generation sequencing to identify genetic variants, including single nucleotide variants (SNVs), insertions, deletions and copy number variants (CNVs) |
Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
---|---|---|---|---|---|---|
630540 | THRB Gene Sequencing | 630276 | Result | 51969-4 | ||
630540 | THRB Gene Sequencing | 630278 | Interpretation | 50397-9 | ||
630540 | THRB Gene Sequencing | 630279 | Footnotes | 8251-1 | ||
630540 | THRB Gene Sequencing | 630280 | PDF Image | 80563-0 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf